SOLO-2 (ENGOT-GCIG/AstraZeneca)

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

Contact Person
Status
Completed
Disease Site
Recurrent Ovarian
Lead Cooperative Group
Participating Groups
AGO
MITO
AGO-AUST
BGOG
GCIG Number